Dr Arunkumar Subramanian

Dr Arunkumar Subramanian

  • Post-Doctoral Research Fellow
  • School of Pharmacy
Faculty of Medical and Life Sciences
SDGs Focus

Biography

Dr Arunkumar Subramanian is a researcher specializing in neuropharmacology and translational drug discovery, with a focus on bioactive compounds such as resveratrol derivatives and Schiff base molecules for Alzheimer鈥檚 disease, obesity, and the gut microbiome. He integrates in-silico methods, including molecular docking, dynamics, and network pharmacology, with in-vitro and in-vivo validation.

He has expertise in preclinical studies using rodent and zebrafish models to assess therapeutic efficacy, toxicity, and underlying mechanisms. His work emphasizes multi-target strategies to bridge computational predictions with clinically relevant outcomes.

Academic & Professional Qualifications

  • Bachelor of Pharmacy, Vinayaka Missions Research Foundation, India (2017)
  • Master of Pharmacy (Pharmacology), The Tamilnadu Dr. MGR Medical University, India (2020)
  • PhD (Pharmacy), SRM Institute of Science and Technology, India, (2025)

Research Interests

  • Neuropharmacology
  • Gut microbiome
  • Drug discovery
  • Preclinical Research
  • Gut Brain Axis

Teaching Areas

  • Pharmacology
  • Toxicology
  • Biochemistry
  • Medicinal Chemistry

Notable Publications

  1. VS A, Subramanian A, Rajendran K, Thamaraikani T, Kumarasamy V, Lian MS, Nordin RB, Sekar M, Subramaniyan V, Karnam M, Sackiriyas S, Wong LS, 鈥淔ructose consumption and metabolic hypertension in rats: a systematic review and meta analysis鈥, PeerJ., 13, e20097, 2025.

  2. Dutta S, Subramanian A, Kumarasamy V, Tamilanban T, Begum MY, Sekar M, Subramaniyan V, Gan SH, Wong LS, Al Fatease A, Wu YS, Muralikrishnan A. 鈥淣etwork
    Pharmacology of Natural Polyphenols for Stroke: A Bioinformatic Approach to Drug Design鈥, Adv Appl Bioinform Chem., 17, pp. 203-219, 2025.

  3. Deepalakshmi M, Sudharsan M, Rajalakshmi S, Boopathi D, Suganya P, Subramanian A, Rajamohamed H. 鈥淒rug-induced acneiform breakout in a postpartum psychosis patient: A case report with literature review鈥, Journal of Pharmacology and Pharmacotherapeutics. 2025.

  4. A. Subramanian, T. Tamilanban, A. D. I. Abdullah, V. Chitra, M. Sekar, G. Swaminathan, I. Yadav, V. Manimaran, V. Rajakumari, and V. Subramaniyan, "Safety assessment of resveratrol surrogate molecule 5 (RSM5): Acute and sub-acute oral toxicity studies in BALB/c mice", Toxicol. Rep., 14, pp. 101956, 2025.

  5. F. Bistagnino, A. Subramanian, and M. R. Tovani Palone, "Navigating the (post-) pandemic landscape: An analysis of COVID-19鈥檚 current status and future implications", Disaster Med. Public Health Prep., 19, pp. e44, 2025.

  6. A. Subramanian, R. Haitharali, N. S., T. Tamilanban, S. Dhanasekaran, S. Gnanasekaran, M. Manavalan, and S. Raja, "Carbamazepine-induced Stevens Johnson Syndrome: A case report with review of the literature", Current Drug Safety, 20(3):382-387, 2025.

  7. A. Subramanian, V. Kumarasamy, M. Y. Begum, M. Sekar, V. Subramaniyan, L. S. Wong, and A. Al Fatease, "Exploring the connections: Autophagy, gut microbiota, and inflammatory bowel disease pathogenesis", J. Inflamm. Res., 17, pp. 10453鈥10470, 2024.

  8. A. Subramanian, T. Tamilanban, V. Subramaniyan, M. Sekar, V. Kumar, A. K. Janakiraman, and S. Kayarohanam, "Establishing network pharmacology between natural polyphenols and Alzheimer鈥檚 disease using bioinformatic tools鈥揳n advancement in Alzheimer鈥檚 research", Toxicol. Rep., 13, pp. 101715, 2024.

  9. A. Subramanian, J. Mohanbabu, T. Srinivasan, T. Tamilanban, V. Subramaniyan, V. Manimaran, M. Sekar, and L. S. Wong, "Reviewing the literature of 3D printing of bones and cartilage: Evidence and practice", Ann. 3D Print. Med., 16, pp. 100180, 2024.

  10. A. Reshma, A. Subramanian, V. Kumarasamy, T. Tamilanban, M. Sekar, S. H. Gan, V. Subramaniyan, L. S. Wong, N. N. I. M. Rani, and Y. S. Wu, "Neurocognitive effects of proanthocyanidin in Alzheimer鈥檚 disease: A systematic review of preclinical evidence", Braz. J. Med. Biol. Res., 57, pp. e13587, 2024.